Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections

References

• Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130:1–45
   PubMedGoogle Scholar
• Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347–82
   PubMed Web of Science ®Google Scholar
• Saint S, Flaherty KR, Abrahamse P, et al. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther 2001;23: 499–512
   PubMed Web of Science ®Google Scholar
• Bonnefoy A, Girard AM, Agouridas C, et al. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997;40:85–90
   PubMed Web of Science ®Google Scholar
• Nord CE, Farrell DJ, Leclercq R. Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections. Microb Drug Resist 2004;10:255–63
   Google Scholar
• Lorenz J. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections. Int J Clin Pract 2003;57:519–29
   PubMed Web of Science ®Google Scholar
• Hagberg L, Carbon C, van Rensburg DJ, et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir Med 2003;97:625–33
   PubMed Web of Science ®Google Scholar
• Aventis. Ketek® (telithromycin) Tablets. 2005. Available from www.fda.gov/cder/foi/label/2005/21144s001,003lbl.pdf [Accessed 12 April 2005]
   Google Scholar
• Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515–23
   PubMed Web of Science ®Google Scholar
• Roos K, Baz M, Leroy B, et al. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. J Infect 2005;50:210–20
   PubMed Web of Science ®Google Scholar
• Fogarty C, Zervos M, Tellier G, et al. Telithromycin for the treatment of acute exacerbations of chronic bronchitis. Int J Clin Pract 2005;59:296–303
   PubMed Web of Science ®Google Scholar
• Bryskier A. Ketolides – telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000;6:661–9
   PubMed Web of Science ®Google Scholar
• Sultan E, Namour F, Mauriac C, et al. HMR 3647, a new ketolide antimicrobial, is metabolized and excreted mainly in feces in man. J Antimicrob Chemother 1999;44(Suppl A):54
   Google Scholar
• Perret C, Lenfant B, Weinling E, et al. Pharmacokinetics and absolute oral bioavailability of an 800 mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy 2002;48:217–23
   PubMed Web of Science ®Google Scholar
• Bhargava V, Lenfant B, Perret C, et al. Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand J Infect Dis 2002;34:823–6
   PubMed Web of Science ®Google Scholar
• Aventis. Ketek® (telithromycin) briefing document for the FDA anti-infective drug products advisory committee meeting, January 2003. Available from www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf [Accessed 12 April 2005]
   Google Scholar
• Edlund C, Alvan G, Barkholt L, et al. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother 2000;46:741–9
   PubMed Web of Science ®Google Scholar
• Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001;45:170–5
   PubMed Web of Science ®Google Scholar
• Cantalloube C, Bhargava V, Sultan E, et al. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int J Antimicrob Agents 2003;22:112–21
   PubMed Web of Science ®Google Scholar
• Shi J, Montay G, Hardy P, et al. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Pharmacotherapy 2005;25:42–51
   PubMed Web of Science ®Google Scholar
• Shi J, Montay G, Chapel S, et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol 2004;44:234–44
   PubMed Web of Science ®Google Scholar
• Khair OA, Andrews JM, Honeybourne D, et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001;47:837–40
   PubMed Web of Science ®Google Scholar
• Muller-Serieys C, Soler P, Cantalloube C, et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother 2001;45: 3104–8
   Google Scholar
• Muller-Serieys C, Andrews J, Vacheron F, et al. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004;53:149–57
   PubMed Web of Science ®Google Scholar
• Low DE, Felmingham D, Brown SD, et al. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. J Infection 2004;29:115–25
   Google Scholar
• Nicolau DP. Clinical use of antimicrobial pharmacodynamic profiles to optimize treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin. Expert Opin Pharmacother 2004;5:229–35
   PubMed Web of Science ®Google Scholar
• Vesga O, Bonnat C, Craig WA. In vivo pharmacodynamic activity of HMR 3647, a new ketolide [Abstract F255]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto, Canada
   Google Scholar
• Pluim J. Population pharmacokinetics support the convenient once-daily 800 mg dosage of telithromycin in patients with upper and lower RTIs, including special populations. Clin Microbiol Infect 2001;7(Suppl 1):266
   Google Scholar
• Sultan E, Lenfant B, Wable C, et al. Pharmacokinetic profile of the new ketolide HMR 3647 800mg once daily in elderly volunteers. J Antimicrob Chemother 1999;44(Suppl A):54
   Google Scholar
• Davey PG. The pharmacokinetics of clarithromycin and its 14- OH metabolite. J Hosp Infect 1991;19(Suppl A):29–37
   Google Scholar
• Rodvold K. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;37:385–98
   PubMed Web of Science ®Google Scholar
• Shi J, Montay G, Leroy B, et al. Effects of ketoconazole and itraconazole on the pharmacokinetics of telithromycin, a new ketolide antibiotic [Abstract A1833]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2002, San Diego, CA
   Google Scholar
• Shi J, Chapel S, Montay G, et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 2005;43:123–33
   PubMed Web of Science ®Google Scholar
• Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005;44:915–34
   PubMed Web of Science ®Google Scholar
• Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746–51
   PubMed Web of Science ®Google Scholar
• Labbe G, Flor M, Lenfant B. Cytochrome P-450 activity is not inhibited in vitro by telithromycin (HMR 3647), a new ketolide [Abstract 09.23]. In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, January 26–28, 2000, Seville, Spain
   Google Scholar
• Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides. Focus on respiratory tract infections. Drugs 2001;61:443–98
   Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109\(Suppl 1):III50–7
   Google Scholar
• Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001;35:26–31
   PubMed Web of Science ®Google Scholar
• Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197–207
   Google Scholar
• Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871–8
   PubMed Web of Science ®Google Scholar
• Wallace Jr RJ, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171: 747–50
   PubMed Web of Science ®Google Scholar
• Lippert C, Leese PT, Sultan E. Telithromycin (HMR 3647) does not interact with CYP2D6 substrate paroxetine. Clin Microbiol Infect 2001;7\(Suppl 1):267 [Abstract P1268]
   Google Scholar
• Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001;21\(Suppl 10):253s–72s
   Google Scholar
• Bhargava V, Leroy B, Shi J, et al. Effect of telithromycin on pharmacokinetics of theophylline in healthy volunteers [Abstract A-1832]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2002, San Diego, CA
   Google Scholar
• Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106–31
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Biaxin® (clarithromycin) prescribing information; 2003. Available at www.biaxin.com/pdf/biapi [Accessed 30 November 2004]
   Google Scholar
• Montay G, Shi J, Leroy B, et al. Effects of telithromycin on the pharmacokinetics of digoxin in healthy men [Abstract A-1834]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2002, San Diego, CA
   Google Scholar
• Scholtz HE, Pretorius SG, Wessels DH, et al. Telithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the pharmacodynamics or pharmacokinetics of warfarin in healthy adult males [Abstract 09.30]. In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, January 26–28, 2000, Seville, Spain
   Google Scholar
• Kolilekas L, Anagnostopoulos GK, Lampaditis I. Potential interaction between telithromycin and warfarin. Ann Pharmacother 2004;38:1424–7
   Google Scholar
• Shrader SP, Fermo JD, Dzikowski AL. Azithromycin and warfarin interaction. Pharmacotherapy 2004;24:945–9
   Google Scholar
• O’Reilly RA. Stereoselective interactions of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33–5
   PubMed Web of Science ®Google Scholar
• Horn JR. Drug interactions with antibacterial agents. J Fam Pract 1995;41:81–90
   PubMed Web of Science ®Google Scholar
• Scholtz HE, Sultan E, Wessels D, et al. Telithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives [Abstract 09.29]. In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, January 26–28, 2000, Seville, Spain
   Google Scholar